相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2
Sonia Servitja et al.
ANTI-CANCER DRUGS (2012)
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer
Patricia K. Corey-Lisle et al.
CANCER (2012)
Docetaxel combined with targeted therapies in metastatic breast cancer
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2012)
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
Teemu T. Junttila et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Mark Barok et al.
CANCER LETTERS (2011)
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Paul Hamberg et al.
CLINICAL BREAST CANCER (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer
Beth Sherrill et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
Shaheenah Dawood et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Gail D. Lewis Phillips et al.
CANCER RESEARCH (2008)
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
Andrew D. Seidman et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer
Karen Bullock et al.
ONCOLOGIST (2008)
Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review
Julie Lemieux et al.
PSYCHO-ONCOLOGY (2008)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
Thomas M. Suter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
DT Eton et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
